United States: New Proposed Medicare Part B Drug Reimbursement Model Raises Questions

Jeffrey Mittleman is a Partner and Ilenna Stein is an Associate in the Boston office


  • The Centers for Medicare & Medicaid Services (CMS) has announced a new proposed reimbursement model for certain Medicare Part B drugs and biologicals.
  • The proposed structure, called the International Pricing Index (IPI) Model, is premised on the idea that Medicare spending for Part B drugs is increasing and exceeds that of 16 other developed countries by 1.8 times. CMS aims to restructure the Part B drug reimbursement methodology so as to test whether it can more closely track international drug prices and reduce Medicare Part B spending.
  • CMS anticipates that it will issue a proposed rule in spring 2019 and that the IPI Model will be piloted between 2020 and 2025, but the proposed IPI Model itself raises a number of questions. CMS is soliciting comments on all aspects of the proposed IPI Model, with comments due by Dec. 31, 2018.

The Centers for Medicare & Medicaid Services (CMS), part of the U.S. Department of Health and Human Services (HHS), announced a new proposed reimbursement model for certain Medicare Part B drugs and biologicals (together, "drugs") on Oct. 25, 2018. The proposed structure, called the International Pricing Index (IPI) Model, is premised on the idea that Medicare spending for Part B drugs is increasing and exceeds that of 16 other developed countries by 1.8 times. Under Section 1115A of the Social Security Act authorizing CMS to waive certain Medicare requirements, CMS aims to restructure the Part B drug reimbursement methodology so as to test whether it can more closely track international drug prices and reduce Medicare Part B spending. On Oct. 30, 2018, CMS issued an Advance Notice of Proposed Rulemaking (ANPR) regarding its proposed framework for the IPI Model.1 CMS is soliciting comments on all aspects of the proposed IPI Model, with comments due by Dec. 31, 2018.

Current Part B Methodology

Currently, Medicare Part B reimburses2 providers and suppliers for certain drugs that are not reimbursed on a cost or prospective payment system basis, including, for instance, physician-administered drugs, separately billable drugs at independent dialysis facilities and certain statutorily defined drugs. These Part B drugs are reimbursed based on the lesser of the actual charge on the claim or 106 percent of the Average Sales Price (ASP).3 CMS contends that the ASP methodology incentivizes physicians to prescribe and furnish more expensive drugs because the reimbursement formula is a percentage of a drug's price.

Proposed IPI Model Details

Drugs and Participating Providers

As proposed, the IPI Model will be used to reimburse the costs of single-source drugs, biologicals, biosimilars and multiple-source drugs with a single manufacturer that are administered in physician practices and hospital outpatient departments in randomized geographic areas, which represent 50 percent of Medicare Part B spending on separately reimbursable Part B drugs.4 For physician practices and hospitals within the geographic areas that are yet to be determined, participation would be mandatory. CMS is soliciting feedback on whether to expand the IPI Model's scope to include additional drugs, how to incorporate newly approved or marketed drugs, whether other Part B providers and suppliers that administer the included drugs should participate or if certain providers or suppliers should be excluded from participation, how to operationalize participation by large provider networks and how to determine the geographic areas to include.


Instead of directly reimbursing providers, the IPI Model proposes utilizing and reimbursing private-sector vendors. The IPI Model contemplates that these vendors will assume the financial risk of negotiating for, taking title to and billing for the eligible drugs, and in turn, the vendors will distribute eligible drugs to participating physician practices and hospital outpatient departments. CMS envisions that these vendors will aggregate purchasing, negotiate volume-based discounts, and utilize electronic ordering, various delivery options and onsite stock replacement mechanisms.

CMS will allow providers to contract with multiple vendors, and CMS hypothesizes that the flexible methodologies employed by vendors will increase competition. The vendors, however, would be prohibited from paying physician groups and hospital outpatient departments rebates or volume-based incentive payments, and according to a press release by HHS, the vendors would not operate formularies. Furthermore, CMS suggests that the contracts vendors enter into with providers could include physicians and hospitals paying vendor services fees and perhaps covering some of the vendors' costs. CMS seeks input concerning, among other questions, the types of entities that could qualify as vendors, appropriate guardrails if manufacturers or healthcare providers can qualify as vendors, the responsibilities imposed upon the vendors and the permissibility of vendor contracts with providers including vendor costs.


Moreover, instead of reimbursing the vendors for participating drugs at 106 percent of ASP, CMS proposes that under the IPI Model, it would pay vendors a Target Price, unless the ASP reimbursement rate is lower. The Target Price would be based on an international price index that includes pricing information from Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Netherlands and the United Kingdom.

Calculating the Target Price would entail the following: averaging the international price for each drug on a standard comparable unit, calculating the ratio of Medicare spending using the ASP prices, establishing the Target Price (which would vary for each drug) by multiplying the IPI by a factor that would result in approximately a 30 percent reduction in Medicare spending, and phasing in the Target Price over the five-year model period by blending the ASP rate and Target Price.5 CMS contends that the IPI Model will remove incentives for physicians prescribing more expensive drugs, as well as narrow the gap in drug prices between the United States and other countries. CMS seeks input regarding which existing and publically available data sources to rely on to establish the IPI in the short-term, whether to require manufacturers to report international sales data in the future, which countries to use in calculating the IPI and how to monitor the international market to account for changes.

CMS additionally intends to reimburse physicians and hospitals a "drug add-on amount," which could be a per encounter or per month amount that would not vary based on the price of the drug. By still providing physicians and hospitals with some reimbursement, CMS believes it will reduce providers' financial risk associated with purchasing and managing drug inventory. However, CMS is soliciting feedback as to whether to establish a payment amount for each drug class, physician specialty or physician practice, as well as whether to allow bonus pools to incentivize prescribing less expensive drugs or practicing evidence-based utilization.


CMS anticipates that it will issue a proposed rule in spring 2019 and that the IPI Model will be piloted between 2020 and 2025.

Impact and Uncertainties

In the ANPR, CMS seeks input regarding many aspects of its proposed framework; however, the IPI Model proposal itself raises a number of questions.

Is CMS Exceeding Its Authority?

First, it is unclear whether CMS has the statutory authority to bypass Congress in establishing a new payment methodology under Medicare Part B. Although CMS is authorized to waive certain provisions under Medicare to "test innovative payment and services delivery models to reduce program expenditures ... while preserving or enhancing the quality of care furnished,"6 adopting a mandatory test that accounts for 50 percent of national Medicare Part B drug spending may exceed that authority. To the extent the IPI Model will be mandatory and replace the statutorily based ASP methodology for half of Part B drug spending, CMS appears to be establishing a new Medicare reimbursement methodology, rather than merely testing a new model in a limited manner. If the IPI Model proceeds as currently proposed, CMS likely will face challenges and be required to defend its authority to pilot this wide-sweeping approach to Part B drug reimbursement.


Given the number of questions surrounding the vendors, it is unclear which entities will elect to participate as vendors. Likely, only those entities with an existing infrastructure in place to buy and distribute drugs would opt to participate, but even such entities may want to avoid receiving direct Medicare reimbursement and potentially be subjected to direct liability under federal healthcare laws, such as the federal False Claims Act and the numerous participation requirements related to Medicare compliance.

Moreover, while the IPI Model aims to reduce Medicare Part B spending, the proposed Model would essentially insert into the Part B drug supply chain a new intermediary entity that will need to not only cover its costs of doing business but also be profitable in order to incentivize vendors to participate. This design begs the question of whether the IPI Model will in fact be able to achieve its goal of reducing costs, or whether it instead will increase them. It is similarly unclear whether the IPI Model will effectively create or reduce efficiencies for providers, who already have purchasing agreements in place and would now have to contract with potentially multiple vendors to obtain included Part B drugs. Further, requiring providers to obtain included Part B drugs from vendors raises questions about unintended distribution issues that could potentially affect patient access and quality of care.


Fundamental questions also exist as to the appropriateness of comparing the Medicare Part B spending to international prices, especially those paid by single-payer systems, such as the United Kingdom's National Health Service (NHS). That is, while CMS certainly is within its authority to try to reduce Medicare Part B spending, it is unclear that international prices are the right index to use for comparison.

Impact on the 340B Program

CMS acknowledges in the ANPR, without much discussion, that the IPI Model has the potential to affect the 340B Program,7 which enables covered entities, including certain hospitals, to purchase heavily discounted outpatient drugs in order to earn a profit when billing for those drugs. CMS states that the IPI Model could affect the maximum price a manufacturer can charge for a covered drug under the 340B Program (340B ceiling price) to the extent the IPI Model could affect a drug's Average Manufacturer Price (AMP) or Best Price, both of which are utilized in the calculation of the 340B ceiling price and could be potentially lowered by sales to vendors under the IPI Model.8

However, to the extent that vendors, not hospitals, would now be responsible for buying and obtaining reimbursement for Part B drugs, 340B hospitals in the participating IPI Model geographic region may no longer have the opportunity to buy and bill for drugs under the 340B Program, and they would lose the revenue generated through the 340B Program. CMS fails to discuss this impact, but the IPI Model may need to be redefined to exclude 340B hospitals from participating in the IPI Model so as not to adversely affect the 340B Program.


Finally, in light of the number of questions on which CMS seeks input and the many details yet to be determined concerning the IPI Model's framework, it seems unlikely that CMS will be able to meet its ambitious goal of publishing a proposed rule in spring 2019 and setting an implementation date of spring 2020. To do so, CMS would have to resolve all of its questions, publish a proposed rule and a final rule, and operationalize all aspects of the IPI Model. From a practical perspective, operationalizing the Model would entail, for instance, establishing a process and enough time for vendors to submit – and CMS to evaluate and award – bids to participate in the Model; allowing enough time for vendors to obtain appropriate licensure to buy and distribute drugs to the extent additional state licensure is necessary; enabling vendors to negotiate with manufacturers and participating providers; analyzing the international data; and determining the Target Price for each drug.

Notwithstanding the number of logistical obstacles the IPI Model appears to face prior to its implementation, affected industry players are encouraged to weigh in and submit comments by Dec. 31, 2018, to shape any future iteration of this proposed Part B pricing model.


1 83 Fed. Reg. 54546 (Oct. 30, 2018).

2 From 2006 to 2008, CMS also allowed physicians to participate in the competitive acquisition program (CAP), in which physicians could elect to purchase Part B drugs from an approved vendor who provided the drug to the physician's office, billed Medicare and collected patient co-pays. See 42 U.S.C. §1395w-3b; 42 C.F.R. §§414.906, 414.908. Payment under the CAP model was tied to ASP, only one vendor participated in the program, and the CAP model has been suspended as of Jan. 1, 2009. See 83 Fed. Reg. at 54549 (discussing the CAP model).

3 42 U.S.C. §1395w-3a(b)(1); 42 C.F.R. §§414.900, 414.904(a). ASP is defined as the manufacturer's sales price, inclusive of all discounts, to all non-excluded purchasers in the U.S. for drug in a calendar quarter, divided by the total number of units sold by the manufacturer of the drug in the calendar quarter. 42 U.S.C. §1395w-3a(c)(1), (3).

4 CMS proposes excluding end-stage renal disease drugs, radiopharmaceuticals, drugs that the U.S. Food and Drug Administration (FDA) identifies as being in short supply, and drugs paid under miscellaneous or "not otherwise classified" codes, such as compounded drugs.

5 In the ANPR, CMS provides a chart that in Year 1, reimbursement would be based 80 percent on ASP and 20 percent on the Target Price; by Year 5, CMS would reimburse 100 percent of the Target Price.

6 42 U.S.C. §1315a(1).

7 See 42 U.S.C. §256b.

8 The 340B ceiling price is calculated utilizing a drug's Average Manufacturer Price (AMP) minus the Medicaid Best Price. AMP is the average price paid to manufacturers in the U.S. by wholesalers and retail community pharmacies purchasing directly from the manufacturer, though with respect to inhalation, infusion, instilled, implanted or injectable drugs (5i drugs), 5i AMP includes sales to physicians and hospitals, among other entities. 42 C.F.R. §§447.504(a), 447.504 (d). Best Price is the lowest price available from the manufacturer for brand-name drugs to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity or governmental entity in the U.S. under any pricing structure. 42 C.F.R. §447.505(a).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions